Sign in

Private company

Better Therapeutics, Inc.

American health services company that raised $8.9 million in 2024 (SEC Form D)1

In its 2023 annual report the company says: “We are a prescription digital therapeutics company developing a clinically validated, software-based novel form of CBT to address the root causes of cardiometabolic diseases. We are developing a proprietary platform of FDA regulated software-based PDTs for the treatment of cardiometabolic diseases by addressing the underlying causes of the diseases. Our initial development efforts are focused on type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and chronic kidney disease.”53 It is headquartered in San Francisco, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryServices-Health Services1
  • HeadquartersSan Francisco, California1
  • Incorporated inDE2
  • Business address548 Market St. #49404, San Francisco, Ca 941012
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-79037.5%Operating margin3
-79837.5%Net margin3
-$5.8MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Research and development94¢$3.7M
  • Interest3¢$100.0K
  • Income tax4¢$153.0K

Out of $8.0K in revenue.3 The company lost money this year.

Financial statements

Fiscal year20192020
Revenue$8.0K3
Research and development$3.7M3
Operating expenses
Operating income-$6.3M3
Interest$100.0K3
Income before tax
Income tax$153.0K3
Net income-$6.4M3
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare Better Therapeutics, Inc. with another company

Corporate structure

Better Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Better Therapeutics, Inc.

  • Better Therapeutics, Inc. San Francisco, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Better Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$7.7M6 Dec 31, 2022$6.6M6 Dec 31, 2021+16.7%
Property and equipment, before depreciation$178.0K6 Dec 31, 2022$310.0K6 Dec 31, 2021−42.6%
Accumulated depreciation$57.0K6 Dec 31, 2022$228.0K6 Dec 31, 2021−75.0%
Property and equipment, net$121.0K6 Dec 31, 2022$82.0K6 Dec 31, 2021+47.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$15.7M6 Dec 31, 2022$40.6M6 Dec 31, 2021−61.2%

Leadership

Who has led Better Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Suying Liu2021
  2. Kevin J. Appelbaum2021–2022
  3. Frank Karbe2023

Chief financial officer

  1. Mark Heinen2023
2025
Board members and other officers (16)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorDavid Perry named Apr 21, 2023 to Jan 23, 202424
  • DirectorGeoffrey Parker named Apr 21, 2023 to Jan 23, 202424

Former names

  • Mountain Crest Acquisition Corp IINov 18, 2020 to Oct 28, 20212

Timeline

  1. Mar 21, 20248-K Debt or obligation accelerated25
  2. Mar 15, 20248-K Listing notice or transfer; Executive or director change26
  3. Mar 14, 20248-K Listing notice or transfer; Other events27
  4. Mar 11, 20248-K Regulation FD disclosure28
  5. Mar 4, 20248-K Regulation FD disclosure29
  6. Jan 8, 20248-K Entered a material agreement; Results of operations; Unregistered sale of shares30
  7. Dec 18, 20238-K Listing notice or transfer31
  8. Dec 13, 20238-K Entered a material agreement32
  9. Nov 30, 20238-K Entered a material agreement; Other events33
  10. Nov 20, 20238-K Executive or director change34
  11. Nov 9, 20238-K Results of operations35
  12. Oct 30, 20238-K Results of operations; Shareholder vote36
  13. Jul 31, 2023New chief executive Frank Karbe becomes CEO7
  14. Nov 1, 2021New chief executive Kevin J. Appelbaum becomes CEO9
  15. Jan 8, 2021New chief executive Suying Liu becomes CEO8

Calendar

When it reported results

  1. Jan 8, 2024Reported quarterly or annual results30
  2. Nov 9, 2023Reported quarterly or annual results35
  3. Oct 30, 2023Reported quarterly or annual results36
  4. Aug 9, 2023Reported quarterly or annual results37
  5. May 11, 2023Reported quarterly or annual results38
  6. Mar 30, 2023Reported quarterly or annual results39
  7. Nov 14, 2022Reported quarterly or annual results40
  8. Aug 11, 2022Reported quarterly or annual results41

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

254 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 46 major events, 90 insider forms, 18 large holders, 3 private raises, 88 other. The latest 20:

  1. May 30, 202415-12G EDGAR
  2. May 28, 2024EFFECT EDGAR
  3. May 28, 2024EFFECT EDGAR
  4. May 28, 2024EFFECT EDGAR
  5. May 28, 2024EFFECT EDGAR
  6. May 28, 2024EFFECT EDGAR
  7. May 23, 2024POS AM EDGAR
  8. May 23, 2024POS AM EDGAR
  9. May 23, 2024POS AM EDGAR
  10. May 23, 2024POS AM EDGAR
  11. May 23, 2024POS AM EDGAR
  12. May 23, 2024S-8 POS EDGAR
  13. May 23, 2024S-8 POS EDGAR
  14. Mar 21, 2024424B3 EDGAR
  15. Mar 21, 20248-K EDGAR
  16. Mar 15, 2024424B3 EDGAR
  17. Mar 15, 20248-K EDGAR
  18. Mar 14, 2024424B3 EDGAR
  19. Mar 14, 20248-K EDGAR
  20. Mar 11, 20248-K EDGAR

The 254 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

39 open-market trades by officers, directors and large owners since October 2021: 39 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 27, 2023PERRY DAVID PExecutive ChairmanBuy1,233,045$0.73$900.1KForm 4
Jul 27, 2023Berman Mark A.Chief Medical OfficerBuy54,802$0.73$40.0KForm 4
Jul 27, 2023Armanino Andrew J.DirectorBuy274,010$0.73$200.0KForm 4
Jul 27, 2023Granger ElderDirectorBuy34,251$0.73$25.0KForm 4
Jul 27, 2023KARBE FRANKChief Executive OfficerBuy137,005$0.73$100.0KForm 4
Jul 27, 2023Parker Geoffrey M.DirectorBuy685,025$0.73$500.1KForm 4
May 16, 2023Granger ElderDirectorBuy600$0.87$522Form 4
Apr 10, 2023David P. Perry 2015 Trust10% ownerBuy4,969,697$0.83$4.1MForm 4
Apr 10, 2023KARBE FRANKChief Executive OfficerBuy242,424$0.83$201.2KForm 4
Apr 10, 2023Parker Geoffrey M.DirectorBuy303,030$0.83$251.5KForm 4
Apr 10, 2023Armanino Andrew J.DirectorBuy303,030$0.83$251.5KForm 4
Sep 16, 2022David P. Perry 2015 Trust10% ownerBuy39,156$2.07$81.1KForm 4
Sep 15, 2022David P. Perry 2015 Trust10% ownerBuy10,844$1.99$21.6KForm 4
Sep 15, 2022KARBE FRANKChief Executive OfficerBuy50,000$2.09$104.5KForm 4
Sep 13, 2022Heinen MarkChief Financial OfficerBuy26,132$1.94$50.7KForm 4
Sep 12, 2022Heinen MarkChief Financial OfficerBuy23,868$1.94$46.3KForm 4
Jun 24, 2022Heinen MarkChief Financial OfficerBuy2,281$1.75$4.0KForm 4
Jun 14, 2022Armanino Andrew J.DirectorBuy15,000$1.39$20.9KForm 4
Jun 13, 2022Parker Geoffrey M.DirectorBuy25,000$1.45$36.2KForm 4
Jun 10, 2022Heinen MarkChief Financial OfficerBuy5,000$1.56$7.8KForm 4

All 39 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 9, 2024Raised $250,000 in a private offering of equity Form D: 1 investor so far Form D
  2. Jul 27, 2023Raised $2.1 million in a private offering of equity Form D: 10 investors so far Form D
  3. Apr 6, 2023Raised $6.5 million in a private offering of equity Form D: 9 investors so far Form D

SEC filer profile

How Better Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBetter Therapeutics, Inc.1
  • CIK0001832415
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)8000 Services-Health Services1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address548 Market St. #49404, San Francisco, CA 941011
  • Phone415-887-23111
  • Shares outstanding47,403,398 as of Nov 3, 20235
  • Public float$15.3M as of Jun 30, 20226
  • On EDGAR sinceNov 18, 20201
  • Filings320 in all: 4 (85), 8-K (51), 3 (20), 424B3 (18), 425 (15), EFFECT (14), CORRESP (13), UPLOAD (10)1
    All 38 form types

    10-Q (9), SC 13G/A (9), SC 13G (8), POS AM (7), S-1/A (6), S-4/A (5), DEF 14A (4), S-1 (4), SC 13D/A (4), 10-K (3), 424B5 (3), 8-K/A (3), D (3), NT 10-Q (3), S-3 (3), 25-NSE (2), S-3/A (2), S-8 (2), S-8 POS (2), SC 13D (2), 10-Q/A (1), 15-12G (1), 424B4 (1), 8-A12B (1), ARS (1), CERT (1), DRS (1), PRE 14A (1), RW (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 30, 2023
    Quarterly report (10-Q) Nov 9, 2023
    Proxy statement (DEF 14A) Oct 16, 2023
    Latest 8-K (8-K) Mar 21, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53